Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal
This article was originally published in PharmAsia News
Executive Summary
Dong-A ST’s in-house developed DPP-4 inhibitor evogliptin is set to enter major markets, including the US and Europe, through a new licensing deal with Tobira that will focus on the treatment of non-alcoholic steatohepatitis (NASH) rather than diabetes.